Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Azafaros

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 08, 2026

From Azafaros

Via Business Wire

Azafaros Further Strengthens Its Board of Directors With Appointment of Biotech Entrepreneur Dr. Thierry Abribat

December 11, 2025

From Azafaros

Via Business Wire

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

July 28, 2025

From Azafaros

Via Business Wire

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing

June 09, 2025

From Azafaros

Via Business Wire

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders

May 13, 2025

From Azafaros

Via Business Wire

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

September 10, 2024

From Azafaros

Via Business Wire

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

June 08, 2023

From Azafaros

Via Business Wire

Azafaros Appoints Chief Operating Officer and Head of Finance

March 20, 2023

From Azafaros

Via Business Wire

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

February 20, 2023

From Azafaros

Via Business Wire

Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102

January 05, 2023

From Azafaros

Via Business Wire

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

March 24, 2022

From Azafaros

Via Business Wire

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

February 14, 2022

From Azafaros

Via Business Wire

Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

February 01, 2022

From Azafaros

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.